

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:	
Mary Jane Cardosa et al.	) Group Art Unit: 1648
Application No.: 10/786,380	) Examiner: STACY BROWN CHEN
Filed: February 24, 2004	Confirmation No.: 3579

For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS

ANTIGENS, AND THE USE THEREOF IN VACCINES

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

The listed foreign and non-patent literature documents are either of record in prior application no. 09/147,919, filed September 23, 1997, upon which applicant relies for the benefits provided in 35 U.S.C. § 120, or are attached.

Application No.: 10/786,380

Applicant respectfully requests that the Examiner consider the listed documents

and indicate that they were considered by making appropriate notations on the attached

form.

This submission does not represent that a search has been made or that no

better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claims in the application and Applicant determines

that the cited documents do not constitute "prior art" under United States law, applicant

reserves the right to present to the office the relevant facts and law regarding the

appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the

patentability of the disclosed invention over the listed documents, should one or more of

the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please

By:

charge the fee to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Dated: May 31, 2007

Salvatore J. Arrigo

Reg. No. 46,063

Telephone: 202-408-4160 Facsimile: 202-408-4400

E-mail: arrigos@finnegan.com

-2-

IDS I	Form	PTO/SB/08:	Substitute	for form	1440A/DT	^
IDO I	COLL	FIU/OD/UD.	Subsiline	KOI TOTTI	1449A/P1	ι.

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

C	omplete if Known	A A
Application Number	10/786,380	MAY 3 1 2007
Filing Date	February 24, 2004	MINI O .
First Named Inventor	Mary Jane Cardosa	13
Art Unit	1648	The safety
Examiner Name	Stacy Brown Chen	HADE
Attorney Docket Number	09914-0004-00000	
		···

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No. <sup>3</sup>	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	A10	US-5,494,671	02-27-1996	Ching-Jun Lai et al.		
	A11	US-6,869,793	03-22-2005	Cardosa et al.		
	A12	US-5,369,025	11-29-1994	Nazerian et al.		
	A13	US-6,074,865	06-13-2000	Kelly et al.		
		US-				
		US-				
		US-	1			
		US-	1			
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
	B11	EP 0836648	01-23-1997	Gerd Sutter et al.		
	B12	WO 90/01946	03-08-1990	Ching-Jun Lai et al.		
	B13	WO 92/15672	09-17-1992	Paoletti <i>et al.</i>		

NONPATENT LITERATURE DOCUMENTS				
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>		
C45	BRAY, M. et al., "Monkeys immunized with intertypic chimeric Dengue viruses are protected against wild- type virus challenge," Journal of Virology, 70(6): 4162-4166 (1996).			
C46	DEUBEL, V., et al., "Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against Dengue," Journal of General Virology, 69: 1921-1929 (1988).	-		
C47	YAMSHCHIKOV, V. F., et al., "Generation of long flavivirus expression cassettes by in vivo recombination and transient dominant selection," Gene, 149: 193-201 (1994).			
C48	ZHANG et al., BBRC 200(1):95-101 (1994).			
C49	MOSS, Seminars in Immunology 2:317-327 (1990).			
C50	HAYES et al., Pediatric Infectious Disease Journal 11(4):311-7, abstract only cited.			
C51	BANCROFT, Puerto Rico Health Sciences Journal 6(11):23-6, abstract only cited.			
	No.¹ C45 C46 C47 C48 C49 C50	Cite No. <sup>1</sup> Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  C45 BRAY, M. et al., "Monkeys immunized with intertypic chimeric Dengue viruses are protected against wild-type virus challenge," Journal of Virology, 70(6): 4162-4166 (1996).  C46 DEUBEL, V., et al., "Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against Dengue," Journal of General Virology, 69: 1921-1929 (1988).  C47 YAMSHCHIKOV, V. F., et al., "Generation of long flavivirus expression cassettes by in vivo recombination and transient dominant selection," Gene, 149: 193-201 (1994).  C48 ZHANG et al., BBRC 200(1):95-101 (1994).  C49 MOSS, Seminars in Immunology 2:317-327 (1990).  C50 HAYES et al., Pediatric Infectious Disease Journal 11(4):311-7, abstract only cited.		

Examiner	Date	
Signature	Considered	